SANA MVD1

lastresort

Explorer
Joined
Mar 10, 2026
Messages
447
Reaction score
0
Location
NorthEast US
SANA MVD1 isn't a peptide at all — it's a salicylic acid derivative that went through a Phase 1A clinical trial not long ago.

Its mechanism has nothing in common with GLP1 analogues, amylin, or calcitonin receptors, so it won't do anything for appetite. What it is, though, is a thermogenic compound unlike others, speeding up fat loss in both mice and humans by as much as 3% of body weight over 15 weeks.

From what's described, the molecule drives ATP to be "wasted" via a futile substrate cycle: ATP gets used to phosphorylate creatine, then phosphocreatine is dephosphorylated back into creatine, with the free energy given off as heat instead of being harnessed for mechanical or chemical work. This cycle raises mitochondrial ATP demand and respiration, so fuel gets burned with no net useful output.

In brown/beige thermogenic fat, the sequence proposed is:

  1. ATP → ADP + phosphocreatine (PCr)

    Creatine kinase spends ATP to phosphorylate creatine:

    Cr+ATP→PCr+ADP\mathrm{Cr + ATP \rightarrow PCr + ADP}Cr+ATP→PCr+ADP
  2. PCr → creatine + inorganic phosphate

    A phosphatase—or some other dephosphorylating activity—takes the phosphate off, bringing creatine back:

    PCr+H2O→Cr+Pi\mathrm{PCr + H_2O \rightarrow Cr + P_i}PCr+H2O→Cr+Pi

    White fat normally holds less mitochondria and isn't thermogenic. The scientists' theory, though, was that SANA MVD1 pushes white fat cells to behave like brown fat cells, since they carry creatine kinase and can be driven into creatine/phosphocreatine metabolism
 
Back
Top